-
Home
- About PMI
-
Smoke-free approach
- What is harm reduction?
- Absence of combustion
- Nicotine
- The role of smoke-free products
- Tar
- Tobacco Regulation
Smoke-free approachOffering smoke-free alternatives to adult smokers is a sensible, complementary addition to existing tobacco control strategies.Read More -
Research
- Our Scientific Approach
- Our Findings
- PMI Publications Library
- Literature Reviews
- Independent Studies
- Expert Reports
- Investigator initiated studies (IIS)
- Latest PMI Science Booklet
- Facts and figures on our smoke-free future
ResearchPMI is committed to sharing results as the development and scientific assessment of smoke-free products advance.Read More -
Our Products
- Tobacco Heating System
- Oven Heating System
- MESH Vaping System
- Disposable Vaping System
- Oral Nicotine Pouches
- Nicotine salts product
Our ProductsPMI believes that offering a range of smoke-free alternatives is essential to ensure individual smokers are able to find a smoke-free product that they can fully switch to.Read More -
News & Events
- Scientific Update Magazine
- Open Science Events
- News
- Conferences Calendar
- Media Library
News & EventsRead our most recent articles and catch up on our latest events and conference presentations.Read More - Contact Us
Systems toxicology analysis of cardiovascular and respiratory endpoints from Apoe-/- mice showed similar effects after switching to a candidate modified risk tobacco product, THS 2.2, or to smoking cessation
Cigarette smoking (CS) is the main risk factor for the development and progression of a series of diseases, including cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD). Suitable animal models play an important role in understanding of smoke-induced pathogenesis. This study examined the development of hallmarks of both COPD and CVD in Apoe-/- mice exposed to either CS or to an aerosol from a candidate modified risk tobacco product, the tobacco heating system (THS2.2) over an 8-month period. In addition to chronic exposure regimes, a comparison of exposure cessation or switching to THS2.2 after 2 months of exposure to CS was performed using a battery of assays (physiological, morphological and molecular). Biological interpretation of various endpoints enables to understand the biological effects of cessation/switching as compared to continuous smoking.
Shotgun lipidomics of rodent tissues
Systems biology reveals anatabine to be an NRF2 activator
Toxicoproteomics reveals an effect of clozapine on autophagy in human liver spheroids
Apical medium flow influences the morphology and physiology of human proximal tubular cells in a microphysiological system
Crowdsourced benchmarking of taxonomic metagenome profilers: lessons learned from the sbv IMPROVER Microbiomics challenge
Reactive oxygen species in the adverse outcome pathway framework: Toward creation of harmonized consensus key events
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.